Guavy Wire
Updated 22:57 UTC
Market news, commentary, and analysis curated and summarized by our AI editorial team.
Santander Blocks American Express Cards in Brazil Amid Partnership End
Santander and American Express have ended their partnership in Brazil, blocking new purchases on Gold and Platinum cards starting September 2026, with the Centurion card to be canceled in October. Customers will retain accumulated points and receive offers for replacement cards.
Canadian Stock Rides Quantum Computing Wave with Cybersecurity Solution
Quantum computing stocks are gaining traction due to government funding and investment. Quantum eMotion, a Canadian company, is working on solutions for commercializing this tech. The stock has seen significant price swings in response to market momentum.
Three Top Dividend Stocks Shine with Strong Growth and Stability
The Globe and Mail recently highlighted three high-quality dividend stocks, including UnitedHealth Group (UNH), which serves as America's largest health insurer, and has a strong track record of growth and stability. The company's recent second-quarter earnings report beat Street estimates, driven by strong Medicare Advantage results.
JNJ Stock Tumbles Amid Clinical Trial Setback
Johnson & Johnson's experimental treatment JNJ-5120/PIPE-307 failed to meet expectations in a major depressive disorder trial, leaving investors wondering about its future prospects. The company's strong dividend profile and financial metrics are attracting attention, but the stock is trading at a premium price relative to its intrinsic value.
Insider Buying and Hefty Price Tags: What's Behind the Market Moves
GameStop's CEO Ryan Cohen has bought $20.38 million worth of GME stock, while Apple's new tablet smartphone device is priced at a steep $1,999. Analysts have raised their price target for Adobe Systems to $340 despite muted revenue growth. JPMorgan Chase analysts believe shares are cheap and will perform well financially.
Apple Stock Rating Maintained Amid Strong iPhone Demand
Evercore ISI has maintained its Outperform rating on Apple stock due to strong iPhone demand, while delivery times are slightly longer than last year's. The company is also addressing an antitrust lawsuit and unveiling a new foldable iPhone model.
Bio-Techne Releases Supplemental Disclosures Amid Shareholder Lawsuit Over Merger
Bio-Techne has released supplemental disclosures regarding its pending merger with Merck KGaA, following a shareholder lawsuit questioning the adequacy of the proxy statement. The company believes the allegations are without merit and its disclosures comply with applicable law. The merger would result in Bio-Techne becoming a wholly owned subsidiary of Merck KGaA, subject to shareholder approval and other customary conditions.
Bio-Techne Supplements Proxy Disclosures Amid Merck KGaA Merger Allegations
Bio-Techne has supplemented its proxy statement to address allegations of proxy disclosure deficiencies related to its proposed merger with Merck KGaA. The company has deemed these allegations meritless and has updated its disclosures to include expanded background and financial advisor information, including Goldman Sachs' valuation ranges ($45, $74; $49, $67; $58, $72) for the proposed merger. A special meeting to vote on the merger is scheduled for September 23, 2026.
Merck's Pipeline Momentum Builds as Company Sees Multiple Catalysts Ahead
Merck presented an upbeat tone at the Morgan Stanley healthcare conference, highlighting its pipeline and commercial strategy. The company's Chairman and Chief Executive Rob Davis said it is 'hitting on all cylinders' with multiple catalysts ahead. Merck also discussed its new oral PCSK9 drug enlicitide, which could expand treatment in a large cardiovascular market.
Merck and Reproductive Medicine Society Partner to Improve Infertility Education
Merck Healthcare Korea and the Korean Society of Reproductive Medicine have signed a memorandum of understanding (MOU) to provide infertility patients with accurate information about treatment. The agreement will last for six months, during which time the two organizations will develop patient-focused educational materials based on research with fertility treatment patients.
Caterpillar's Industrial Strength: Backlog Conversion Drives Momentum
Caterpillar's recent momentum is being driven by its backlog conversion and factory utilization, with analysts closely watching the company's operating activity, financial disclosures, and changes in market conditions. The distinction between trading reactions and measurable business changes remains central to understanding Caterpillar's performance. Key metrics such as cash conversion, operating margins, and customer activity are being closely examined to gauge the company's overall health.
JPMorgan Upgrades IREN to Overweight, Sees 48% Upside
IREN's stock price fell by 4% despite JPMorgan analyst Richard Choe upgrading his rating to Overweight and increasing his price target to $65. The upgrade reflects growing confidence in the company's ability to convert its data center footprint and Nvidia partnership into recurring revenue.